Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.

Remicade (infliximab) - J&J

Taltz (ixekizumab) - Eli Lilly, Japan Tobacco

Bimzelx (bimekizumab) - UCB

brepocitinib (PF-06700841) - Priovant Therap

Cimzia (certolizumab pegol) - Astellas, UCB

Humira (adalimumab) - AbbVie

Tremfya (guselkumab) - J&J

tofacitinib - Generic mfg.

methotrexate - Generic mfg.

Ilumya (tildrakizumab-asmn) - Sun Pharma, Almirall

Cosentyx (secukinumab) - Novartis

Stelara (ustekinumab) - J&J

leflunomide - Generic mfg.

izokibep (ABY-035) - ACELYRIN

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

Simponi (golimumab) - Merck (MSD), Mitsubishi Tanabe, J&J

Rinvoq (upadacitinib) - AbbVie

Siliq (brodalumab) - Bausch Health

apremilast - Generic mfg.

Sotyktu (deucravacitinib) - BMS

Enbrel (etanercept) - Pfizer, Amgen

http://www.ncbi.nlm.nih.gov/pubmed/38503473

Andreas Kerschbaumer; Bente Appel Esbensen; Daniel Aletaha; Dennis G McGonagle; Désirée van der Heijde; Heidi Bertheussen; Iain B McInnes; Jan W Schoones; Josef S Smolen; Kevin L Winthrop; Laure Gossec; Ricardo J O Ferreira; Wolf-Henning Boehncke; Xenofon Baraliakos

Mar 20, 2024